Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes

SGLT2 inhibitors (Invokana, etc) are in the spotlight again.

Reps will say Invokana (canagliflozin) is now approved to reduce risk of CV events in adults with type 2 diabetes and CV disease...while Jardiance (empagliflozin) is only approved to reduce CV death.

But Invokana's approval is based on NONsignificant reductions in CV death, MI, or stroke...lumped into one significant composite outcome.